Wu L, Zhao D, Lan Y, Jin L, Yang L
BMC Pharmacol Toxicol. 2025; 26(1):38.
PMID: 39980035
PMC: 11844164.
DOI: 10.1186/s40360-025-00868-5.
Robinson C, Parker K, Kataria S, Downs E, Supra R, Kaye A
Health Psychol Res. 2022; 10(3):38360.
PMID: 36168642
PMC: 9501833.
DOI: 10.52965/001c.38360.
Jackson K, Argikar U, Cho S, Crouch R, Driscoll J, Heck C
Drug Metab Rev. 2022; 54(3):246-281.
PMID: 35876116
PMC: 10282953.
DOI: 10.1080/03602532.2022.2097254.
Fu D, Wu D, Guo H, Hu Y, Xia Y, Ji X
Front Psychiatry. 2022; 12:780921.
PMID: 35222104
PMC: 8863678.
DOI: 10.3389/fpsyt.2021.780921.
MacKenzie K, Zhao M, Barzi M, Wang J, Bissig K, Maletic-Savatic M
Eur J Pharm Sci. 2020; 153:105488.
PMID: 32712217
PMC: 7506503.
DOI: 10.1016/j.ejps.2020.105488.
Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults.
Lopez P, Torrente F, Ciapponi A, Lischinsky A, Cetkovich-Bakmas M, Rojas J
Cochrane Database Syst Rev. 2018; 3:CD010840.
PMID: 29566425
PMC: 6494390.
DOI: 10.1002/14651858.CD010840.pub2.
The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
Reed V, Buitelaar J, Anand E, Day K, Treuer T, Upadhyaya H
CNS Drugs. 2016; 30(7):603-28.
PMID: 27290715
DOI: 10.1007/s40263-016-0349-0.
ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder.
Connolly J, Glessner J, Elia J, Hakonarson H
Ther Innov Regul Sci. 2015; 49(5):632-642.
PMID: 26366330
PMC: 4564067.
DOI: 10.1177/2168479015599811.
Efficacy and safety of atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorder.
Kohn M, Tsang T, Clarke S
Clin Med Insights Pediatr. 2013; 6:95-162.
PMID: 23641171
PMC: 3620814.
DOI: 10.4137/CMPed.S7868.
Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study.
Molleston J, Fontana R, Lopez M, Kleiner D, Gu J, Chalasani N
J Pediatr Gastroenterol Nutr. 2011; 53(2):182-9.
PMID: 21788760
PMC: 3634369.
DOI: 10.1097/MPG.0b013e31821d6cfd.
Idiosyncratic drug-induced liver injury: a clinical update.
Maddur H, Chalasani N
Curr Gastroenterol Rep. 2010; 13(1):65-71.
PMID: 21049293
DOI: 10.1007/s11894-010-0154-8.
Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.
Dellagnello G, Zuddas A, Masi G, Curatolo P, Besana D, Rossi A
CNS Drugs. 2009; 23(9):739-53.
PMID: 19689165
DOI: 10.2165/11314350-000000000-00000.
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review.
Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D
Neuropsychiatr Dis Treat. 2009; 5:215-26.
PMID: 19557116
PMC: 2695220.
DOI: 10.2147/ndt.s3896.
Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.
Kirchheiner J, Rodriguez-Antona C
CNS Drugs. 2009; 23(3):181-91.
PMID: 19320528
DOI: 10.2165/00023210-200923030-00001.
Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder.
Bangs M, Jin L, Zhang S, Desaiah D, Allen A, Read H
Drug Saf. 2008; 31(4):345-54.
PMID: 18366245
DOI: 10.2165/00002018-200831040-00008.
Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.
Graham J, Coghill D
CNS Drugs. 2008; 22(3):213-37.
PMID: 18278977
DOI: 10.2165/00023210-200822030-00003.
Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
Cheng J, Chen R, Ko J, Ng E
Psychopharmacology (Berl). 2007; 194(2):197-209.
PMID: 17572882
DOI: 10.1007/s00213-007-0840-x.
